A Case of Acute Pulmonary Thromboembolism during Bevacizumab Combination Chemotherapy for Lung Adenocarcinoma-Reference-Cited by-同舟云学术

A Case of Acute Pulmonary Thromboembolism during Bevacizumab Combination Chemotherapy for Lung Adenocarcinoma

Published:2018 Issue:4 Volume:77 Page:267-270
ISSN:0029-0424
Container-title:Journal of Nihon University Medical Association
language:en
Short-container-title:Nichidai Igaku Zasshi

Author:

Nomoto Masayuki¹²,Asai Yasuo¹²,Morita Hiroyuki¹²,Fukuda Asami¹²,Yamada Shiho²,Fukai Yumi¹²,Hayashi Kentaro²,Sato Yoshihiro²,Oki Takashi²,Shimizu Tetsuo²,Takahashi Noriaki²,Hashimoto Shu²

Affiliation:

1. Department of Respiratory Medicine, Mitsuwadai General Hospital

2. Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine

Publisher

The Nihon University Medical Association

Link

https://www.jstage.jst.go.jp/article/numa/77/4/77_267/_pdf

Reference9 articles.

1. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184–2191.

2. Alan Sandler, Robert Gray, Michael C, et al. Paclitaxel– Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer. N Engl J Med 2006; 355: 2542–2550.

3. Martin Reck, Joachim von Pawel, Petr Zatloukal, et al. Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL. J Clin Oncol 2009; 27: 1227–1234.

4. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006– 2012.

5. Aogi K, Masuda N, Ohno S, et al. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Res Treat 2011; 129: 829–838.